Capella Bioscience raises $15.5 mln in Series A funding
London-based Capella Bioscience Ltd raised 11 million pounds ($15.5 million) in a Series A funding round led by Advent Life Sciences, Medicxi Ventures and Osage University Partners. The new capital will support the advancement of Capella's therapeutic antibody discovery programs towards clinical evaluation. In connection with the financing, Bill Harrington of Osage University Partners will join the board in an observer role.
9 March 2016•3 mins read
